Cronos Group Inc

Jim Cramer said Altria’s acquisition of a 45% stake in Cronos Group last week was a “smart move” for Altria.

Through Cronos Group’s partnership with Ginko Bioworks, the company aims to produce cannabis through fermentation.

Cronos Group (CRON) has been on a declining trend for a while. The stock rose to a peak of ~30 Canadian dollars in February.

In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.

On August 23, the markets tumbled due to the escalating trade war. The S&P 500 Index lost around 2.6%. Altria stock held out and lost just 0.4%.

Aurora Cannabis is set to release its fiscal 2020 first-quarter earnings results on November 11. Let’s see what analysts expect for its upcoming quarter.

Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The company has lost 14.81% of its value since October 1.

The Day reported that New York, New Jersey, Connecticut, and Pennsylvania’s governors met and agreed on basic guidelines for legalizing marijuana.

Cannabis is a hot sector that’s constantly evolving. Right now, how to buy cannabis stocks is a question that’s likely on many investors’ minds.

Mexico is ready with a revised proposal to legalize marijuana this year. The Supreme Court gave lawmakers until April 30 to submit the new proposal.

On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec.

Recreational cannabis is close to being legalized in Canada, and producers are running at full bore to capture a piece of the market.

This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.

AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

Apple removed 181 vaping-related apps due to the vape crisis in the US. Canopy Growth is not happy with Apple’s move. Let’s see why.

Aurora Cannabis should report its fourth-quarter earnings results on Thursday. So far, September has been positive. As of Monday, the stock has gained 8.7%.

Marijuana laws are pretty strict in Wisconsin. Although cannabis is spreading its roots across US states, it’s still illegal at the federal level. President Trump and his administration want states to decide. Florida, New York, and Minnesota are all gearing up to legalize adult-use cannabis. Now, Wisconsin is pushing to legalize medical marijuana. Let’s see […]

Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.

Canopy Growth (NYSE:CGC)(TSE:WEED) still has investors’ attention despite all that the marijuana industry has gone through.

According to a Reuters report on December 3, Brazil is ready to approve medical cannabis products. Currently, cannabis is illegal in Brazil.

With Biden strongly opposing full-scale legalization, President Trump could turn around things. President Trump might support medical marijuana legalization.

Vaping has become very popular. However, investigations by the FTC and FDA sparked more concerns. Juul’s vaping devices could cause seizures.

Aphria (APHA) reported its results for the first quarter of fiscal 2020 on October 15. Since then, the stock has fallen 7%.

Canopy Growth (CGC) (WEED) missed analysts’ estimates this year. Analysts had huge expectations from CGC after Canada allowed cannabis in 2018.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Jefferies reduced the target price for Cronos Group stock to $5.3 from $7.5. The stock’s average target price is set at 12.0 Canadian dollars.

Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it’s illegal in Kansas. Even having a small amount is considered a crime.

Canopy Growth (CGC) (WEED) received optimistic views from analysts on Monday. Seaport Global Securities upgraded the stock to “buy” from “neutral.”

Although Joe Biden supported medical cannabis in his previous presidential campaigns, he has always opposed full-scale legalization.

The Canadian Press reported that Canopy Growth is partnering with rapper Drake to launch a new cannabis venture, the More Life Growth Company.

On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

Deloitte estimates that the newly legalized cannabis beverage market could be worth 529 million Canadian dollars annually in Canada.

Canopy Growth (NYSE:CGC) lost 25.4% in 2019. The company reported weak sales and higher-than-expected operating losses in the last two quarters.

After Canada legalized cannabis edibles in October, consumers hoped to buy these products this month. However, three provinces must wait until January.

Canopy Growth (CGC) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29.

On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.

Canopy Growth has struggled this year. Despite all their strategies, cannabis companies have failed to hit revenue and profitability targets this year.

It looks like cannabis stocks had a great day. Innovative Industrial Properties (IIPR), Cronos Group (CRON), and Tilray (TLRY) are all surging today.

Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?

In its Q2 earnings report today, Tilray reported a 371% YoY revenue increase to $45.9 million. Tilray beat analysts’ estimate of $41.1 million in revenue.

Aphria (APHA) has impressed investors with its earnings results this year. Overall, the cannabis industry has struggled due to various headwinds.

Republicans have been conservative about cannabis. However, cannabis legalization is a popular discussion topic among Democrats.

While Aphria’s consensus target price fell after its earnings, most analysts remain bullish on the stock. The overall “strong-buy” rating didn’t change.

New Hampshire legalized medical cannabis, but using cannabis for recreational purposes is still prohibited. The state legalized medical marijuana in 2013.

Marijuana products are top-rated among Americans. Illinois will see recreational marijuana products for sale on January 1.

Bruce Linton, ex-CEO of Canopy Growth (CGC) (WEED), recently had some tips to share with the company’s recently appointed CEO, David Klein.

Cannabis stocks had a difficult 2019. Besides cannabis companies losing out on revenue and profitability, many external factors also affected the sector. While pessimism drove the industry this year, a Raymond James analyst predicts things can turn around in 2020. Let’s take a look. Raymond James feels the cannabis sector could rebound On December 16, […]

On September 18, cannabis stock Tilray (TLRY) popped about 27% to an all-time high of $153.8 in the mid-day session.

Marijuana legalization is ramping up in the US. Pennsylvania legalized medical cannabis in 2016. Now, the state wants to legalize recreational cannabis.

Aphria has successfully impressed investors compared to other cannabis companies this year, even though the same factors have affected the entire industry.

Last week, Innovative Industrial Properties (IIPR) offered $125 million in senior notes, giving initial investors the option to exercise $18.75 million in additional principal amount notes.

Aurora Cannabis (ACB) is going through a rough patch. This year, the company’s stock has lost 60.9% of its value as of December 23.

The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

MKM Partners analyst Bill Kirk likes Cronos Group’s healthy cash position, strong track record, and its relationship with Altria (NYSE:MO).

Marijuana legalization in South Dakota could see daylight in 2020. The state passed measures to legalize both recreational and medical marijuana.

Cannabis players are having a hard time this year. Regulatory concerns and weaker earnings due to the vaping-related crisis took a toll on the sector.

The cannabis earnings season has started again. Earnings season is an exciting time for investors who have been eyeing the sector.

As the cannabis space has increasingly become crowded, companies such as Cronos Group would greatly benefit from a company such as Altria.

Canopy Growth reported a negative EBITDA of 92.1 million Canadian dollars in the first quarter of fiscal 2020. The EBITDA fell 69.2% in the second quarter.

For fiscal 2020, analysts expect Canopy Growth to report revenues of 404.5 million Canadian dollars—a rise of 78.7% from fiscal 2019.

On August 8, Tilray announced that it had received approval to import cannabis into the US to conduct two clinical trials related to cannabidiol.

Recreational cannabis has been legally available to Canadians since October 2018, when Canada legalized it. Recently, the country rolled out Cannabis 2.0.

On July 10, Canopy Growth (WEED) (CGC) announced that it had entered an agreement to acquire Hiku Brands Company (HIKU).

MedMen’s disappointing fourth-quarter results caused the stock price to fall. The company missed analysts’ revenue estimates for the quarter.

Recreational cannabis isn’t legal in Maryland, but the state has been trying to launch edibles as part of its medical marijuana program.

Yesterday, Canopy Growth (CGC) (WEED) announced that it appointed Constellation Brands’ (STZ) CFO David Klein as its new CEO.

So far, cannabis stocks have rebounded in 2020, which investors expected. The marijuana industry struggled in 2019. Overall, the rebound will take time.

For the second quarter of fiscal 2020, analysts expect Hexo’s revenue to grow 25.5% YoY (year-over-year) to 16.8 million Canadian dollars.

In October, Canada completed the second phase of recreational cannabis legalization. This was expected to help drive sales. But that hasn’t been the case.

Cronos Group and Aphria are Jim Cramer’s top picks in the cannabis sector. Aphria’s upbeat earnings results restored investors’ faith in the sector.

Aurora Cannabis (ACB) was trading at a multiple of 26.4x, which declined from 34x in October.

Cannabis legalization has taken a back seat in the US. Since the last Democratic debate, there hasn’t been much discussion about federal legalization.

Macro-economic and political uncertainty across the global market have already taken a toll on Canopy Growth stock (CGC) (WEED).

Marijuana is legal in Vermont for medical and recreational use. However, there are some limitations. The state doesn’t allow marijuana sales yet.

Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.

New Approach Montana resumed its marijuana legalization campaign in May. The group submitted plenty of signatures and qualified for the November ballot.

Analysts expect Altria to report revenues of $5.08 billion in the second quarter of 2020—a fall of 2.2% from $5.19 billion in the second quarter of 2019.

Cannabis companies that have operations in China, especially the ones that manufacture vape products, have been impacted by the coronavirus.

On June 30, Innovative Industrial Properties announced its decision to raise additional capital of $225 million through a public offering of its common stock.

Today, Gaurav Jain of Barclays downgraded Altria Group (NYSE:MO) from “overweight” to “equal weight.” He also lowered his target price from $50 to $43.

Charlotte’s Web Holdings (NYSEARCA:CWEB) is one of the main players in the CBD business. The company plans to keep expanding in 2020.

Cronos Group, one of the more resilient cannabis stocks, hasn’t escaped the gloom in the cannabis sector. It’s down 37.44% year-to-date on the Nasdaq.

OrganiGram (NASDAQ:OGI) stock is trading higher before its third-quarter earnings. The stock closed with a gain of 3.9% at $1.58 on Wednesday.

OrganiGram will likely report its earnings for the third quarter of fiscal 2020 on July 13. We’ll have to see if marijuana stocks recover in July.

On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.

Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”

Aurora Cannabis (NYSE:ACB) announced some business transformation plans on June 23. The plans included cost savings and margin improvement.

While most businesses suffered amid COVID-19, marijuana saw a drastic rise in sales. Many states have been rethinking the benefits of marijuana legalization.

Hexo beat the revenue estimates of 19.9 million Canadian dollars. However, the company reported a quarterly EBITDA loss of 4.3 million Canadian dollars.

Lorne Steinberg thinks that even after Hexo’s deal with Molson Coors, it still doesn’t look attractive. He would rather find value somewhere else.

Layoffs amid COVID-19 led to a decline in disposable income, which had a negative impact on the cigarette and cannabis industries.

So far this year, Philip Morris International (NYSE:PM) and Altria Group (NYSE:MO) have underperformed the broader equity markets.

Tilray (NASDAQ:TLRY) posted its first-quarter earnings on May 11. The revenue growth was impressive in the first quarter.

On April 7, the NYSE sent a listing notification to Hexo. The warning said that the stock fell below the NYSE’s $1.00 share price continued listing standard.

Aurora Cannabis (NYSE:ACB) reported its third-quarter results on May 14. The earnings report was a surprise for most analysts and investors.

Marijuana companies in the US have been struggling to get financial and banking access. Cannabis still isn’t legal at the federal level.

Green Thumb Industries (OTCMKTS:GTBIF) will likely report its results for the first quarter of fiscal 2020 on May 14 after the market closes. 

Cronos Group (NASDAQ:CRON) reported its results for the first quarter of fiscal 2020 on May 8. The revenue growth was stronger.